BIO-1211 是高度选择性的、口服有效的α4β1 (VLA-4)抑制剂，对 α4β1 和 α4β7 的IC50分别为 4 nM 和 2 μM。

BIO-1211 is a more potent inhibitor of α4β1 (VLA-4, IC50 = 4 nM) over α4β7(IC50 = 2 μM).

BIO-1211 does not show activity against α1β1, α5β1, α6β1, αLβ2 and αIIbβ3[2].

In naive, C57BL/6 mice, BIO-1211 exhibited a considerable depletion in the EAE clinical score, which correlated with decreased expression of TNF-α, IL-17, IFN-γ and pervade of CD11b+ and CD45+ cells into the cerebral cortex. BIO-1211 resulted in reduced cytokines expression, leukocyte trafficking, and inhibition of inflammatory responses in a dose-independent manner[1].

187735-94-0

C36H48N6O9

708.80

DMSO:250 mg/mL (352.71 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years